Protein-small molecule interactions in neocarzinostatin, the prototypical enediyne chromoprotein antibiotic

被引:31
作者
Baker, James R.
Woolfson, Derek N.
Muskett, Frederick W.
Stoneman, Rhys G.
Urbaniak, Michael D.
Caddick, Stephen
机构
[1] UCL, Christopher Ingold Labs, Dept Chem, London WC1H 0AJ, England
[2] Univ Bristol, Sch Chem, Bristol BS8 1TS, Avon, England
[3] Univ Leicester, Dept Biochem, Biol NMR Ctr, Leicester LE1 9HN, Leics, England
[4] Univ Dundee, Sch Life Sci, Div Biol Chem & Mol Microbiol, Dundee DD1 5EH, Scotland
基金
英国医学研究理事会; 英国工程与自然科学研究理事会;
关键词
chromoprotein; drug delivery; enediyne; ligand; neocarzinostatin;
D O I
10.1002/cbic.200600534
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The enediyne chromoproteins ore a class of potent antitumour antibiotics comprising a 1:1 complex of a protein and a noncovalently bound chromophore. The protein is required to protect and transport the highly labile chromophore, which acts as the cytotoxic component by reacting with DNA leading to strand cleavage. A derivative of the best-studied member of this class, neocarzinostatin (NCS), is currently in use as a chemotherapeutic in Japan. The application of the chromoproteins as therapeutics along with their unique mode of action has prompted wide-spread interest in this area. Notable developments include the discovery of non-natural ligands for the apoproteins and the observotion that multiple binding modes are available for these ligands in the binding site. Mutation studies on the apoproteins have revealed much about their stability and variability, and the w application of an in vitro evolution method has conferred ne binding specificity for unrelated ligands. These investigations hold great promise for the application of the apoproteins for drug-delivery, transport and stabilisation systems.
引用
收藏
页码:704 / 717
页数:14
相关论文
共 71 条
[1]   THE 7-STRANDED BETA-BARREL STRUCTURE OF APO-NEOCARZINOSTATIN AS COMPARED TO THE IMMUNOGLOBULIN DOMAIN [J].
ADJADJ, E ;
QUINIOU, E ;
MISPELTER, J ;
FAVAUDON, V ;
LHOSTE, JM .
BIOCHIMIE, 1992, 74 (9-10) :853-858
[2]   The calicheamicin gene cluster and its iterative type I enediyne PKS [J].
Ahlert, J ;
Shepard, E ;
Lomovskaya, N ;
Zazopoulos, E ;
Staffa, A ;
Bachmann, BO ;
Huang, KX ;
Fonstein, L ;
Czisny, A ;
Whitwam, RE ;
Farnet, CM ;
Thorson, JS .
SCIENCE, 2002, 297 (5584) :1173-1176
[3]  
ALLEY MC, 1988, CANCER RES, V48, P589
[4]   Efficacy and tolerability of gemtuzumab ozogamicin (anti-CD33 monoclonal antibody, CMA-676, Mylotarg®) in children with relapsed/refractory myeloid leukemia [J].
Brethon, Benoit ;
Auvrignon, Anne ;
Galambrun, Claire ;
Yakouben, Karima ;
Leblanc, Thierry ;
Bertrand, Yves ;
Leverger, Guy ;
Baruchel, Andre .
BMC CANCER, 2006, 6 (1)
[5]   Synthetic ligands for apo-neocarzinostatin [J].
Caddick, S ;
Muskett, FW ;
Stoneman, RG ;
Woolfson, DN .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2006, 128 (13) :4204-4205
[6]   Crystallization and preliminary X-ray crystallographic studies of a macromolecular antitumour antibiotic, C1027 [J].
Chen, Y ;
Shao, R ;
Bartlam, M ;
Li, J ;
Jin, L ;
Gao, Y ;
Liu, Y ;
Tang, H ;
Zhen, Y ;
Rao, Z .
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY, 2002, 58 :173-175
[7]   SEQUENTIAL H-1, C-13, AND N-15 NMR ASSIGNMENTS AND SOLUTION CONFORMATION OF APOKEDARCIDIN [J].
CONSTANTINE, KL ;
COLSON, KL ;
WITTEKIND, M ;
FRIEDRICHS, MS ;
ZEIN, N ;
TUTTLE, J ;
LANGLEY, DR ;
LEET, JE ;
SCHROEDER, DR ;
LAM, KS ;
FARMER, BT ;
METZLER, WJ ;
BRUCCOLERI, RE ;
MUELLER, L .
BIOCHEMISTRY, 1994, 33 (38) :11438-11452
[8]   Anti body-targeted chemotherapy with immunoconjugates of calicheamicin [J].
Damle, NK ;
Frost, P .
CURRENT OPINION IN PHARMACOLOGY, 2003, 3 (04) :386-390
[9]   Antibody-targeted chemotherapy with immunoconjugates of calicheamicin: Differential anti-tumor activity of conjugated calicheamicin targeted to B-cell lymphoma via B-cell lineage specific molecules CD19, CD20 and CD22. [J].
DiJoseph, JF ;
Armellino, DC ;
Dougher, MM ;
Kunz, A ;
Boghaert, ER ;
Hamann, PR ;
Zinkewich-Peotti, K ;
Damle, NK .
BLOOD, 2004, 104 (11) :683A-683A
[10]   Structures of in vitro evolved binding sites on neocarzinostatin scaffold reveal unanticipated evolutionary pathways [J].
Drevelle, A ;
Graille, M ;
Heyd, B ;
Sore, I ;
Ulryck, N ;
Pecorari, F ;
Desmadril, M ;
van Tilbeurgh, H ;
Minard, P .
JOURNAL OF MOLECULAR BIOLOGY, 2006, 358 (02) :455-471